Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The investigators propose to leverage the unique infrastructures and expertise of National
Centre for Parasitology Entomology and Malaria Control and the Pasteur Institute in Cambodia
and combine modern fieldwork, including a mobile laboratory fully equipped for molecular
biology and culture experiments, with state-of-the-art genomic analyses to investigate how
Plasmodium vivax parasites respond to antimalarial drugs. The investigators will focus on
resistance to CQ, the choice treatment for vivax malaria in most endemic countries, for which
treatment failures have been reported in Cambodia. The study will address some of the key
biological mechanisms limiting the efficiency of drug therapy in P. vivax, including the
identification of genetic polymorphisms underlying drug resistance in Cambodian P. vivax. The
findings will provide a first unbiased perspective on the mechanisms of drug resistance in P.
vivax and have the strong potential to significantly improve malaria control in Southeast
Asia.
Phase:
Phase 4
Details
Lead Sponsor:
Institut Pasteur, Cambodia
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)